Effectiveness of a digital health application (levidex) on quality of life in people with multiple sclerosis: A pragmatic, randomized controlled trial (LAMONT)

In a pragmatic randomized controlled trial involving 470 people with multiple sclerosis and impaired quality of life, the digital therapeutic levidex, when added to standard care, significantly improved disease-specific quality of life, depressive symptoms, and social functioning compared to standard care alone.

The Gist

Imagine living with Multiple Sclerosis (MS) as driving a car that has a very reliable engine (the medication that stops the disease from attacking your nerves), but the car's interior is uncomfortable, the radio is static-filled, and the GPS keeps giving you confusing directions. You can drive the car, but the journey is exhausting, stressful, and lowers your overall enjoyment of the ride.

This study, called the LAMONT trial, asked a simple question: Can a digital "co-pilot" app help make that journey smoother and more enjoyable?

Here is the breakdown of the study in plain English, using some everyday analogies.

1. The Problem: The "Invisible" Struggle

Medication for MS is great at stopping the physical damage, but it doesn't fix the "invisible" problems: fatigue, stress, low mood, and the feeling that your quality of life is slipping. Many people with MS feel like they are stuck in a foggy room, even if their car (body) is technically running.

2. The Solution: The Digital Co-Pilot (Levidex)

The researchers tested an app called Levidex. Think of this app not as a doctor, but as a smart, 24/7 life coach that lives in your pocket.

• How it works: It's a web-based program with 16 "conversations" (modules). It uses a chat-like format to guide you through topics like stress management, healthy eating, sleep, and exercise.
• The Magic: It's not just a static textbook. It uses algorithms to create a "simulated dialogue," asking you questions and tailoring its advice based on your answers, much like a personal trainer who adjusts your workout plan based on how you feel that day.

3. The Experiment: The Race

The researchers gathered 470 people with MS who were already feeling a bit down on their quality of life. They split them into two teams:

• Team A (The Control Group): Got their usual medical care (the "engine" and the "mechanic") plus a simple pamphlet with links to websites.
• Team B (The Intervention Group): Got their usual medical care PLUS the Levidex app (the "smart co-pilot").

They ran this race for 6 months.

4. The Results: Who Won?

At the finish line, Team B (with the app) did significantly better.

• The Score: On a scale measuring how happy and functional they felt, Team B improved more than Team A.
• The "NNT" (Number Needed to Treat): This is a fancy way of saying, "How many people need to use the app for one person to get a real, noticeable benefit?" The answer was 9. This means if you give this app to 9 people with MS, one of them will experience a significant boost in their quality of life that they wouldn't have gotten from just standard care.
• Other Wins: The app also helped with depression and the ability to work or socialize. It didn't quite fix anxiety (the "worry monster" was still there), but it did a lot of heavy lifting elsewhere.
• Safety: No one got hurt. In fact, people loved the app. They gave it high satisfaction scores, saying it felt helpful and easy to use.

5. Why This Matters

Imagine you have a broken leg. The cast (medication) holds the bone together so it can heal. But the cast doesn't teach you how to walk again, how to stay positive while you're stuck, or how to eat right to heal faster.

This study shows that adding a digital tool to standard medical care is like adding physical therapy and a cheerleader to the cast. It doesn't replace the doctor or the medicine, but it fills the gaps that medicine can't reach.

The Bottom Line

For people with MS who are struggling with their daily life and mood, adding this specific digital app to their routine is a small but powerful step forward. It's a scalable, affordable way to give patients a "co-pilot" to help navigate the emotional and lifestyle challenges of living with a chronic disease.

In short: The medicine fixes the engine, but the app helps you enjoy the ride.

Technical Summary

1. Problem Statement

People with Multiple Sclerosis (pwMS) frequently suffer from impaired health-related quality of life (QoL) due to "invisible symptoms" such as fatigue, cognitive difficulties, and emotional distress, which are often not addressed by standard Disease-Modifying Drugs (DMDs). While Digital Therapeutics (DTx) offer a scalable solution, previous trials have yielded mixed results due to two primary limitations:

• Ceiling Effects: Previous studies often included participants with high baseline QoL, leaving little room for measurable improvement.
• Control Group Issues: Prior trials compared DTx against active controls (e.g., other digital programs) rather than Treatment As Usual (TAU), making it difficult to determine the additive value of the intervention in a real-world clinical setting.

The LAMONT trial aimed to address these gaps by evaluating the efficacy of levidex, a digital therapeutic, as an adjunct to TAU specifically in a population of pwMS with pre-existing, impaired QoL.

2. Methodology

• Study Design: A pragmatic, parallel-group, randomized controlled trial (RCT) conducted fully remotely (online) between November 2023 and December 2024.
• Participants: $N = 470$ pwMS (aged $\ge$18) with physician-confirmed MS and impaired QoL (defined as a Hamburg Quality of Life Questionnaire in Multiple Sclerosis [HAQUAMS] score $\ge$2). Participants were recruited via online campaigns and physician referrals.
• Interventions:
  • Intervention Group (IG): Received levidex + TAU. Levidex is a web-based DTx developed by GAIA Group, utilizing rule-based algorithms to generate personalized "simulated dialogues." It consists of 16 sequential modules (30–45 mins each) covering MS self-management, psychological strategies (CBT-based), diet, physical activity, and sleep. It integrates behavior change techniques (e.g., goal setting, cognitive restructuring) and mindfulness.
  • Control Group (CG): Received TAU alone (routine outpatient care, including DMDs, psychotherapy, or no active treatment) plus a brief digital information sheet with public MS resources.
• Outcomes:
  • Primary Endpoint: MS-specific QoL at 6 months, measured by the total score of the HAQUAMS.
  • Secondary Endpoints: Depressive symptoms (PHQ-9), social/work functioning (WSAS), MS-specific QoL (MusiQoL), anxiety (GAD-7), and instrumental activities of daily living (FAI).
  • Exploratory Endpoints: Health care utilization, DMD adherence, and user satisfaction (NPS, ZUF-8).
• Statistical Analysis:
  • Intention-to-Treat (ITT) analysis using ANCOVA with baseline scores as covariates.
  • Missing data handled via bootstrapped maximum-likelihood multiple imputation.
  • A hierarchical gatekeeping strategy was applied to control for multiplicity in secondary outcomes.
  • Sample size was calculated to detect a Cohen's $d$ of 0.30 with 80% power, accounting for 25% attrition.

3. Key Contributions

• Targeted Population: Unlike previous trials, this study specifically recruited patients with impaired QoL, successfully avoiding ceiling effects and demonstrating efficacy in a clinically relevant, symptomatic population.
• Real-World Comparison: By using a TAU-only control rather than an active control, the study isolates the specific additive benefit of the DTx over standard care, providing robust evidence for clinical integration.
• Regulatory Milestone: The trial served as the pivotal study for the permanent inclusion of levidex in the German Digital Health Applications (DiGA) directory, establishing a pathway for reimbursement and prescription in Germany.
• Scalable Intervention: It demonstrates that an automated, self-guided, multi-domain digital intervention can achieve clinically meaningful outcomes without requiring intensive human therapist resources.

4. Results

• Primary Outcome (HAQUAMS at 6 months):
  • The IG showed a statistically significant improvement compared to the CG.
  • Baseline-adjusted mean difference: $-0.10$ points ($95\%$ CI $-0.18$ to $-0.03$;$p = 0.008$).
  • Effect Size: Cohen's $d = 0.26$.
  • Clinical Relevance: 39.5% of the IG achieved a Minimal Clinically Important Difference (MCID $\ge$0.22) compared to 27.8% in the CG.
  • Number Needed to Treat (NNT): 9.
• Secondary Outcomes:
  • Significant Improvements: Depressive symptoms (PHQ-9, $p=0.025$), social/work functioning (WSAS, $p=0.003$), and MusiQoL global index ($p=0.020$).
  • Non-Significant: Anxiety symptoms (GAD-7) and instrumental activities of daily living (FAI).
• Adherence & Safety:
  • High adherence: IG participants completed a mean of 10.0 out of 16 modules.
  • Safety: No serious adverse events or adverse device effects were reported.
  • Satisfaction: High user satisfaction (NPS of 31.5 at 6 months; ZUF-8 mean score 3.2/4).
• Subgroup Analysis: Effects were consistent across most subgroups, with significant improvements observed in women and those taking antidepressants or not on DMDs.

5. Significance

The LAMONT trial provides robust evidence that adding a scalable, automated digital therapeutic (levidex) to standard care significantly improves QoL, mood, and functioning in pwMS with impaired quality of life.

• Clinical Impact: It validates a "digital-first" approach to managing the psychosocial and behavioral aspects of MS, which are often neglected in pharmacological treatment.
• Health Policy: The successful trial design and positive outcomes facilitated the permanent inclusion of levidex in the German DiGA directory, setting a precedent for how DTx can be evaluated and reimbursed in national healthcare systems.
• Future Directions: The study suggests that while effect sizes are modest, the scalability and low resource burden of such interventions offer population-level value. Future research should focus on stepped-care models (combining digital tools with human support for non-responders) and longer-term sustainability.

Limitations Noted: The study relied on self-reported outcomes (potential for bias), had a 6-month follow-up (limiting long-term sustainability data), and the unblinded design could not fully separate specific intervention effects from non-specific factors like expectancy. However, the authors argue that patient perception is the most valid metric for QoL and that the design reflects real-world clinical practice.